ES 
EN 
DE 
A research-focused comparison of Melanotan II and PT-141, covering melanocortin receptor selectivity, evidence, safety signals and regulatory status.
This article is educational in nature and constitutes a review of the published scientific literature on telomere biology and biomarkers of cellular ageing. It describes molecular mechanisms and the state of research, rather than use in humans. The text does not constitute medical or diagnostic advice. Some of the tools discussed (telomere length tests, epigenetic clocks) belong to the field of experimental research and diagnostics.
Telomeres are repetitive stretches of DNA at the ends of chromosomes, protecting them from degradation and end-to-end fusion. With each division of a somatic cell the telomere shortens slightly — which is why its length is studied as one of the determinants of cellular ageing and as a biomarker of biological age, alongside other molecular markers.
A linear chromosome has two ends, and each end is a problem. Without protection, the free end of a DNA strand looks to the cell like damage — the site of a break that the repair machinery attempts to “stitch” together. Were such stitching to occur, chromosomes would start to fuse end to end, leading to genetic chaos at division. The solution that evolution developed is the telomere.
A telomere is a special structure at the end of a chromosome, built from a short DNA sequence repeated many times over. In humans and other vertebrates this is the sequence TTAGGG, repeated from hundreds to several thousand times at a single end. These repeats do not encode proteins — they serve a structural and protective function. Together with a set of associated proteins (a complex called shelterin), the telomere “caps” the end of the chromosome so that the cell does not read it as damage.
An analogy that captures this role well is the plastic tip of a shoelace. As long as the tip is intact, the lace does not fray. A telomere works in a similar way — it protects the actual, coding part of the chromosome from “fraying” and from accidental fusion with another chromosome. As long as the telomere is sufficiently long, the cell treats the end of the chromosome as natural rather than as a defect to be repaired.
Important for the topic of ageing is that telomere length is not constant. In most cells of the body it decreases over time — and it is precisely this change that has made telomeres the subject of intensive gerontological research.
Telomere shortening arises from a fundamental limitation in the way DNA is copied. It is known as the end replication problem.
During each division, the cell must copy all of its genetic material. It does so using an enzyme — DNA polymerase. This enzyme, however, has a limitation: it can only extend a new strand in one direction and needs a short “starter” (primer) from which to begin. On one of the strands this leads to a situation in which the very end of the linear DNA molecule cannot be fully copied — once the last primer is removed, a small, unreplicated fragment remains. As a result, each successive copy of the chromosome is slightly shorter at the end than the previous one.
Were this loss to affect genes, it would be a catastrophe. Because, however, the ends carry telomeres — a buffer composed of non-coding TTAGGG repeats — it is these that absorb the loss. With each division the telomere loses some of its repeats, protecting the coding part of the chromosome. The telomere thus acts as an expendable buffer: it shortens so that the rest of the chromosome remains intact.
This process, however, has its limit, first described even before the telomeres themselves were understood.
The Hayflick limit. In the 1960s Leonard Hayflick observed that human somatic cells cultured in the laboratory do not divide indefinitely — after a certain, relatively constant number of divisions (on the order of a few dozen) they stop dividing. This boundary was named the Hayflick limit. For years it was unclear what determined it. Later work linked it precisely to telomere shortening: when a telomere shortens to a critical length, the cell registers this as an alarm signal.
The effect of reaching this boundary is replicative senescence — a permanent arrest of division. A senescent cell usually does not die at once; it remains alive and metabolically active, but no longer divides. In the framework of ageing biology, critical telomere shortening is therefore sometimes described as one of the “counters” limiting the capacity of tissues to renew themselves. For this reason telomere length is sometimes compared to an internal division counter — with the caveat that this is a model, and the physiology of the whole organism is considerably more complex.
It is worth noting that the rate of telomere shortening does not depend solely on the number of divisions. In studies, shortening is also influenced by oxidative stress and inflammation — factors that can accelerate the loss of telomere repeats independently of replication itself. This is one of the reasons why telomere length is studied in the context of lifestyle and chronic stress, and not merely as a simple division counter.
Since telomeres shorten with each division, a question arises: how does the organism maintain division-capable cells throughout life at all, and the species — across generations? The answer is an enzyme capable of rebuilding telomeres: telomerase.
Telomerase is an enzyme that can add TTAGGG repeats to the end of a chromosome, counteracting their loss. It is a ribonucleoprotein — a complex of protein and an RNA molecule. The protein subunit (encoded by the TERT gene, telomerase reverse transcriptase) performs the catalytic function, while the built-in RNA molecule (the TERC component) serves as an internal template according to which the enzyme synthesises successive repeats. In this way telomerase solves the end replication problem — it adds what DNA polymerase cannot copy.
Not all cells, however, have active telomerase. This distinction is at the heart of the entire topic:
At this point an important ambiguity arises, one that the literature describes explicitly. The silencing of telomerase in somatic cells is neither an accident nor an imperfection — it is sometimes interpreted as a protective mechanism. A cell deprived of telomerase has a limited “division limit”, which hinders uncontrolled proliferation. It is no coincidence that most cancer cells reactivate telomerase (or another mechanism for maintaining telomeres) — reactivation of this enzyme is one of the features allowing a cancer cell to divide essentially without end. Telomerase activity is therefore observed in most cancers and for this reason is itself a target of oncological research — including as a potential point of attack for anticancer therapies.
For this reason the question “since telomerase lengthens telomeres, is its activation beneficial” has no simple answer. An enzyme that in stem cells favours renewal may, in a damaged cell, favour its uncontrolled proliferation. This ambiguity — regeneration on one hand, oncological risk on the other — is a constant element of the scientific discussion of telomerase and the reason why rigorous accounts avoid presenting “telomerase activation” as an unambiguously desirable goal.
Discovery and the Nobel Prize. For explaining how telomeres and telomerase protect chromosomes, Elizabeth Blackburn, Carol Greider and Jack Szostak were awarded the Nobel Prize in Physiology or Medicine in 2009. Their work — the identification of telomere repeats and the discovery of telomerase itself — laid the foundations for the whole of modern telomere biology.
The relationship between telomere shortening and ageing has been studied at many levels: from cell cultures, through animal models, to population observations in humans. The picture that emerges from them is consistent in direction, but requires interpretive caution.
The cellular level. In cultures, what the model predicted has been confirmed: somatic cells lose telomeres with successive divisions, and after reaching a critical length they enter replicative senescence. This is the best-documented part of the picture — observed directly under in vitro conditions.
The organism level. In observational studies in humans, the average telomere length (most often measured in blood leukocytes) at the population level decreases with age. Shorter telomeres have also been linked in some studies to age-related diseases. These are, however, primarily correlational associations — they show co-occurrence, they do not prove that telomere shortening is the direct cause of a given disease. Large inter-individual variability (in people of the same age, telomere length can vary considerably) further complicates drawing simple conclusions.
Stress and lifestyle. A prominent line of research (including work by the teams of Elizabeth Blackburn and Elissa Epel) linked chronic psychological stress with shorter telomeres and lower telomerase activity in immune cells. These results popularised telomeres as a “biomarker” of the burden on the organism, but here too caution applies: these are correlational observations in a complex context, not proof of a simple cause-and-effect relationship.
The table below organises the main lines of research together with the nature of the evidence.
| Area of research | Model / context | Observation | Year | Source |
|---|---|---|---|---|
| Telomere shortening with divisions | Culture of human somatic cells | Progressive telomere shortening, entry into senescence upon reaching the limit | 1990 | Harley et al. |
| Telomeres and age — population | Humans (observational, leukocytes) | Average telomere length decreases with age | — | population studies (reviews) |
| Chronic stress and telomeres | Humans (observational) | Shorter telomeres and lower telomerase activity associated with chronic stress | 2004 | Epel et al. |
| Telomerase in cancer | Cancer / cellular tissues | Telomerase reactivation in most cancers studied | — | Shay and Wright |
The common denominator of these studies is that telomere shortening is one of the determinants of cellular ageing, and not its sole or “principal” cause. Modern ageing biology describes many parallel processes accompanying age; telomere shortening is one of them. Treating telomere length as a single “age” of the organism would be a simplification that the literature itself avoids.
Telomere length is not the only molecular way of estimating “biological age” — that is, the state of the organism as read from cellular markers, not necessarily consistent with chronological age. A parallel, and today often more accurate, research tool are epigenetic clocks.
The epigenetic clock is based on the phenomenon of DNA methylation — a chemical modification (the attachment of a methyl group) at specific sites in the genome that does not change the DNA sequence but affects gene activity. The pattern of methylation changes in a predictable way with age. In 2013 Steve Horvath described a set of methylation positions on the basis of which the age of a tissue can be estimated with surprising accuracy — this model (the so-called Horvath clock) became a point of reference for the entire field. Subsequent generations of epigenetic clocks followed, refined for various research applications.
It is worth distinguishing these two markers, because they are sometimes confused:
Both are research biomarkers — tools for describing and measuring the processes accompanying ageing. Neither is an intervention: they measure a state, they do not change it. This matters, because in popular messaging it is easy to confuse “a marker that reflects something” with “a lever that can be pulled”.
Commercial biological age tests are appearing on the market — based on telomere length or on DNA methylation. They should be treated as part of the field of experimental diagnostics and research, rather than as a routine tool of established clinical value. Their results can be subject to methodological variability, and the interpretation of a single measurement in a specific individual is limited. This article describes these tests solely as an area of research — it contains no encouragement to undergo them, nor any guidance on interpreting their results.
In the literature of peptide gerontology, molecules analysed in the context of telomerase activity appear. The most frequently cited example is Epithalon — a synthetic tetrapeptide (Ala-Glu-Asp-Gly), studied in cell cultures and animal models for its effect on telomerase activity. The mechanism postulated for this molecule, the quality of the available data, the methodological limitations and a critical appraisal of the literature have been discussed separately — a full account of the mechanism and the state of research can be found in a dedicated article: Epithalon and telomeres — what we know from research. The present text deliberately does not duplicate that analysis; it is limited to noting that peptides of this kind are the subject of basic research on telomerase.
Molecules studied in the context of telomerase — including Epithalon — available on the market as laboratory reagents have Research Use Only status: they are intended solely for research, they are not medicines, dietary supplements or products for use in humans. Data on their effect on telomerase come predominantly from cellular and animal models. There is no basis for claiming that any peptide “lengthens telomeres in humans” or affects lifespan — such formulations go beyond what has been demonstrated in research.
What are telomeres?
Telomeres are repetitive stretches of DNA at the ends of chromosomes, built from the sequence TTAGGG repeated many times over. They do not encode proteins — they serve a protective function, safeguarding the coding part of the chromosome against degradation and against the accidental end-to-end fusion of chromosomes. They are sometimes compared to the plastic tips of a shoelace, which prevent it from fraying.
Why do telomeres shorten?
This results from the so-called end replication problem: DNA polymerase cannot fully copy the very end of a linear chromosome, so each successive copy is slightly shorter at the end. Telomeres absorb the loss, protecting the genes. With each cell division the telomere loses some of its repeats; the rate of shortening is additionally influenced by oxidative stress and inflammation.
What is telomerase?
Telomerase is an enzyme (a ribonucleoprotein) that can add TTAGGG repeats to the ends of chromosomes, counteracting their shortening. Its catalytic part is encoded by the TERT gene. Telomerase is active mainly in stem cells and germ cells, and in most mature somatic cells it remains silenced. Telomerase reactivation is observed in most cancers, which makes it a topic of oncological research.
How do telomeres relate to biological age?
Telomere length is sometimes used as one of the biomarkers of biological age, because at the population level it decreases with age. It is, however, a marker with large inter-individual variability and mainly correlational associations. Another, often more accurate research marker is the epigenetic clock based on DNA methylation (the Horvath model). Both are tools for measuring a state, not interventions.
Is it possible to lengthen telomeres?
This question belongs to the field of research, not to practice. In cell cultures, telomerase can lengthen telomeres, yet its activity is bound up with a fundamental ambiguity: the same enzyme that in stem cells favours renewal is, in most cancers, reactivated and favours uncontrolled proliferation. For this reason the literature does not present “lengthening telomeres” as an unambiguously desirable goal, and this article contains no recommendations, protocols or promises in this regard — it describes solely the state of knowledge.
This content is educational in nature and constitutes a review of the published scientific literature on the biology of telomeres, telomerase and biomarkers of ageing. The mechanisms and results described relate in large part to cellular and animal models and to correlational observations in humans; they do not constitute medical or diagnostic advice. The article contains no guidance on how to “lengthen telomeres”, and makes no promises regarding lifespan, rejuvenation or “life extension”. Telomere length tests and epigenetic clocks are described solely as an area of research and experimental diagnostics. Substances studied in the context of telomerase, available as reagents, have Research Use Only status — they are not medicines or products for use in humans.
A research-focused comparison of Melanotan II and PT-141, covering melanocortin receptor selectivity, evidence, safety signals and regulatory status.
A research comparison of MK-677 and ipamorelin, focusing on GHS-R1a signaling, selectivity, administration route, human evidence and WADA status.
We offer a wide selection of peptides tailored to a range of laboratory analytical needs.
Every batch is tested for identity and purity (HPLC, MS) and comes with a certificate of analysis.
We invest in analytical testing and full batch documentation for every product.
Nuestras numerosas reseñas positivas reflejan la satisfacción de nuestros clientes que siguen regresando por más.
¡Suscríbete al boletín!
Obtén un 10% de descuento en tu primera compra
One-Peptides.com
Información
© 2026 ONE-PEPTIDES.COM